These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 22272892)

  • 1. Statins and portal hypertension: a new pharmacological challenge.
    Ramírez G; Briceño J; Rojas A
    Curr Vasc Pharmacol; 2012 Nov; 10(6):767-72. PubMed ID: 22272892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Nitric Oxide-Donating Statin Decreases Portal Pressure with a Better Toxicity Profile than Conventional Statins in Cirrhotic Rats.
    Rodríguez S; Raurell I; Torres-Arauz M; García-Lezana T; Genescà J; Martell M
    Sci Rep; 2017 Jan; 7():40461. PubMed ID: 28084470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacologic prevention of variceal bleeding and rebleeding.
    Baiges A; Hernández-Gea V; Bosch J
    Hepatol Int; 2018 Feb; 12(Suppl 1):68-80. PubMed ID: 29210030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins.
    Marrone G; Russo L; Rosado E; Hide D; García-Cardeña G; García-Pagán JC; Bosch J; Gracia-Sancho J
    J Hepatol; 2013 Jan; 58(1):98-103. PubMed ID: 22989565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats.
    Laleman W; Van Landeghem L; Van der Elst I; Zeegers M; Fevery J; Nevens F
    Gastroenterology; 2007 Feb; 132(2):709-19. PubMed ID: 17258737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Celecoxib reduces hepatic vascular resistance in portal hypertension by amelioration of endothelial oxidative stress.
    Tai Y; Zhao C; Zhang L; Tang S; Jia X; Tong H; Liu R; Tang C; Gao J
    J Cell Mol Med; 2021 Nov; 25(22):10389-10402. PubMed ID: 34609050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statins activate the canonical hedgehog-signaling and aggravate non-cirrhotic portal hypertension, but inhibit the non-canonical hedgehog signaling and cirrhotic portal hypertension.
    Uschner FE; Ranabhat G; Choi SS; Granzow M; Klein S; Schierwagen R; Raskopf E; Gautsch S; van der Ven PF; Fürst DO; Strassburg CP; Sauerbruch T; Diehl AM; Trebicka J
    Sci Rep; 2015 Sep; 5():14573. PubMed ID: 26412302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial.
    Abraldes JG; Albillos A; Bañares R; Turnes J; González R; García-Pagán JC; Bosch J
    Gastroenterology; 2009 May; 136(5):1651-8. PubMed ID: 19208350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the transsulfuration-H2S pathway by FXR and GPBAR1 ligands in the treatment of portal hypertension.
    Fiorucci S; Distrutti E
    Pharmacol Res; 2016 Sep; 111():749-756. PubMed ID: 27475883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacologic management of portal hypertension.
    Berzigotti A; Bosch J
    Clin Liver Dis; 2014 May; 18(2):303-17. PubMed ID: 24679496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simvastatin Prevents Progression of Acute on Chronic Liver Failure in Rats With Cirrhosis and Portal Hypertension.
    Tripathi DM; Vilaseca M; Lafoz E; Garcia-Calderó H; Viegas Haute G; Fernández-Iglesias A; Rodrigues de Oliveira J; García-Pagán JC; Bosch J; Gracia-Sancho J
    Gastroenterology; 2018 Nov; 155(5):1564-1577. PubMed ID: 30055171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased hepatic resistance: a new target in the pharmacologic therapy of portal hypertension.
    Hernández-Guerra M; García-Pagán JC; Bosch J
    J Clin Gastroenterol; 2005 Apr; 39(4 Suppl 2):S131-7. PubMed ID: 15758648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular Targets for the Treatment of Portal Hypertension.
    Brusilovskaya K; Königshofer P; Schwabl P; Reiberger T
    Semin Liver Dis; 2019 Nov; 39(4):483-501. PubMed ID: 31315135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New cellular and molecular targets for the treatment of portal hypertension.
    Gracia-Sancho J; Maeso-Díaz R; Fernández-Iglesias A; Navarro-Zornoza M; Bosch J
    Hepatol Int; 2015 Apr; 9(2):183-91. PubMed ID: 25788198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells.
    Vilaseca M; García-Calderó H; Lafoz E; García-Irigoyen O; Avila MA; Reverter JC; Bosch J; Hernández-Gea V; Gracia-Sancho J; García-Pagán JC
    Hepatology; 2017 Jun; 65(6):2031-2044. PubMed ID: 28142199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension.
    Bosch J; Abraldes JG; Fernández M; García-Pagán JC
    J Hepatol; 2010 Sep; 53(3):558-67. PubMed ID: 20561700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathophysiology and a Rational Basis of Therapy.
    Gracia-Sancho J; Maeso-Díaz R; Bosch J
    Dig Dis; 2015; 33(4):508-14. PubMed ID: 26159267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement of portal hypertension and hepatic blood flow in cirrhotic rats by oestrogen.
    Sakamoto M; Ueno T; Nakamura T; Sakata R; Hasimoto O; Torimura T; Sata M
    Eur J Clin Invest; 2005 Mar; 35(3):220-5. PubMed ID: 15733078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tempol administration, a superoxide dismutase mimetic, reduces hepatic vascular resistance and portal pressure in cirrhotic rats.
    García-Calderó H; Rodríguez-Vilarrupla A; Gracia-Sancho J; Diví M; Laviña B; Bosch J; García-Pagán JC
    J Hepatol; 2011 Apr; 54(4):660-5. PubMed ID: 21159403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats.
    Di Pascoli M; Diví M; Rodríguez-Vilarrupla A; Rosado E; Gracia-Sancho J; Vilaseca M; Bosch J; García-Pagán JC
    J Hepatol; 2013 May; 58(5):904-10. PubMed ID: 23262250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.